Skip to content
DataLookout
Menu

Also listed under Autoimmune Diseases

ClinicalTrials.gov term: Lupus Erythematosus, Systemic

Lupus (SLE) clinical trials

Get alerts when Lupus (SLE) trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22

What changed in the last 30 days

38 trials changed in the last 30 days: 1 stopped, 13 with notable changes, 24 with minor changes only.

  1. Minor: BLOSSOM · Intravenous Anifrolumab · Systemic Lupus Erythematosus in Pediatric Participants Trial sites expanded: 103 → 111 locations AstraZenecaPhase 3 NCT05835310
  2. Minor: Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 · Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) Trial sites expanded: 13 → 17 locations AbbViePhase 1 NCT07607964
  3. Notable: PREVENER · Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease Enrollment reduced: 1944 → 1117 participants Instituto de Investigación Marqués de ValdecillaPhase 4 NCT07611747
  4. Notable: Baricitinib · Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis Eligibility criteria changed National Institute of Allergy and Infectious Diseases (NIAID)Phase 1 NCT07262983
  5. Minor: E6742 · Systemic Lupus Erythematosus Trial sites expanded: 54 → 63 locations Eisai Co., Ltd.Phase 2 NCT07515014
  6. Minor: TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus Trial completed South Valley UniversityNot specified NCT07397728
  7. Minor: SOLUNA · Mosunetuzumab · Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Primary completion pushed from Feb 28, 2028 to Aug 11, 2028 Hoffmann-La RochePhase 2 NCT07598396
  8. Minor: Centrally Acting ACE Inhibition in SLE Trial completed Northwell HealthPhase 2 NCT04486118
  9. Notable: ALLEGORY · Obinutuzumab · Systemic Lupus Erythematosus Results posted: Nov 12, 2026 Hoffmann-La RochePhase 3 NCT04963296
  10. Notable: CD19/CD22/BCMA CAR-T Cells (BZE2204) · Relapsed or Refractory Autoimmune Diseases Primary endpoint(s) modified Shanghai Cell Therapy Group Co.,LtdEarly Phase 1 NCT07174843
  11. Minor: GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants Enrollment closed, study ongoing GlaxoSmithKlinePhase 1 NCT06576271
  12. Notable: (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE] Recruitment opened EMD Serono Research & Development Institute, Inc.Phase 3 NCT07840287
  13. Minor: ROSY-S · Rollover Study · Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment Trial sites expanded: 153 → 166 locations AstraZenecaPhase 3 NCT07691970
  14. Stopped: KP104 · Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus Withdrawn before enrolling Kira Pharmacenticals (US), LLC.Phase 2 NCT05504187
  15. Minor: SIRIUS-SLE LTE · Ianalumab · Systemic Lupus Erythematosus (SIRIUS-SLE Extension) Trial sites expanded: 162 → 167 locations Novartis PharmaceuticalsPhase 3 NCT06133972
  16. Minor: 4 trials marked Unknown by the registry's verification sweep Changed Registry verification sweep4 trials
    1. Minor: BAH242 · Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Essen BiotechPhase 1/2 NCT06350110
    2. Minor: Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regulator Cells, IL17/IL-10 Ratio, and Disease Activity in Systemic Lupus Erythematosus Patients Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting Universitas SriwijayaNot applicable NCT06659068
    3. Minor: RAISE · Rare AutoImmune SElf-management Programme Development Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting University of the West of EnglandNot specified NCT06642870
    4. Minor: Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Sohag UniversityNot specified NCT06631404
  17. Notable: Dapa-Active LN · Dapagliflozin in Active Lupus Nephritis Primary completion moved earlier from Jul 2029 to Jul 1, 2028 Brigham and Women's HospitalPhase 4 NCT07323524
  18. Notable: Healthy Adult Participants and · Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body Primary endpoint(s) modified Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 1 NCT07649265
  19. Minor: Cevostamab · Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Trial sites expanded: 1 → 11 locations Genentech, Inc.Phase 1 NCT07629583
  20. Notable: MYTP01 for Immune-Mediated Diseases Start date pushed from Oct 2026 to Dec 2026 Zhejiang Provincial People's HospitalNot applicable NCT07901764
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-11-18 NCT07946367 Dual-targeting of B & T Cell Pathways Evaluation Trial Diabetes Free, Inc. new Phase 1/2
2026-11-12 NCT07931170 Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study Pediatric Nephrology Research Consortium new
2026-11-10 NCT07930091 Molecular Biomarkers for Discriminating Lupus Nephritis in SLE Egyptian Chinese University new
2026-11-03 NCT07913919 Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study University of Cambridge new
2026-10-30 NCT07906145 A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases Shanghai Qilu Pharmaceutical Research and Development Center LTD new Phase 1
2026-10-29 NCT07902622 Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus Erythematosus Foundation University Islamabad new
2026-10-28 NCT07901764 MYTP01 for Immune-Mediated Diseases Zhejiang Provincial People's Hospital new
2026-10-28 NCT07901634 Association of Inflammatory Biomarkers and Ferritin With Severity of Pediatric Systemic… Desy Wulandari new
2026-10-23 NCT07892651 MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) Axiom Bioregistry new
2026-10-09 NCT07868289 Effectiveness of Resonance Frequency Breathing Exercises in Patients With Systemic Lupus… Istanbul University - Cerrahpasa new

Active trials by phase

Early Phase 1
39
Phase 1
117
Phase 1/2
46
Phase 2
62
Phase 2/3
5
Phase 3
41
Phase 4
20
Not charted: 224 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Lupus (SLE) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials